Pharmacophore selection and redesign of non-nucleotide inhibitors of anthrax edema factor

• Published in: Toxins 2012-11, Vol.4 (11), p.1288-1300
• Main Authors: Schein, Catherine H, Chen, Deliang, Ma, Lili, Kanalas, John J, Gao, Jian, Jimenez, Maria Estrella, Sower, Laurie E, Walter, Mary A, Gilbertson, Scott R, Peterson, Johnny W
• Format: Article
• Language: English
• Subjects: Adenosine Triphosphate - metabolism; Adenylyl Cyclase Inhibitors; adenylyl cyclase toxin; Animal models; Animals; Anthrax - drug therapy; Anthrax - microbiology; Anti-Bacterial Agents - chemistry; Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Antigens, Bacterial - chemistry; ATP; Bacillus anthracis - drug effects; Bacillus anthracis - metabolism; Bacillus anthracis - pathogenicity; Bacterial Toxins - antagonists & inhibitors; Bacterial Toxins - chemistry; Binding Sites; computational design; Cyclic AMP - metabolism; Disease Models, Animal; Drug Design; E coli; Edema; fluorenone; Inhibitors; library screening; Ligands; Models, Molecular; Molecular Docking Simulation; Review; Small Molecule Libraries - chemistry; Small Molecule Libraries - pharmacology; Small Molecule Libraries - therapeutic use; Toxins; Waterborne diseases
• ISSN: 2072-6651; 2072-6651
• DOI: 10.3390/toxins4111288

Antibiotic treatment may fail to protect individuals, if not started early enough, after infection with Bacillus anthracis, due to the continuing activity of toxins that the bacterium produces. Stable and easily stored inhibitors of the edema factor toxin (EF), an adenylyl cyclase, could save lives in the event of an outbreak, due to natural causes or a bioweapon attack. The toxin's basic activity is to convert ATP to cAMP, and it is thus in principle a simple phosphatase, which means that many mammalian enzymes, including intracellular adenylcyclases, may have a similar activity. While nucleotide based inhibitors, similar to its natural substrate, ATP, were identified early, these compounds had low activity and specificity for EF. We used a combined structural and computational approach to choose small organic molecules in large, web-based compound libraries that would, based on docking scores, bind to residues within the substrate binding pocket of EF. A family of fluorenone-based inhibitors was identified that inhibited the release of cAMP from cells treated with EF. The lead inhibitor was also shown to inhibit the diarrhea caused by enterotoxigenic E. coli (ETEC) in a murine model, perhaps by serving as a quorum sensor. These inhibitors are now being tested for their ability to inhibit Anthrax infection in animal models and may have use against other pathogens that produce toxins similar to EF, such as Bordetella pertussis or Vibrio cholera.